<DOC>
	<DOCNO>NCT01408030</DOCNO>
	<brief_summary>The purpose NOSE Study carefully examine efficacy safety 3 nasal spray ( bevacizumab , estriol , tranexamic acid ) , compare placebo , treatment HHT relate nosebleed .</brief_summary>
	<brief_title>North American Study Epistaxis HHT</brief_title>
	<detailed_description>140 patient moderate severe epistaxis secondary HHT randomize receive one four intranasal spray period 12 week follow additional 12 week therapy . Enrollment occur period 18-36 month . The primary endpoint frequency epistaxis . Secondary endpoint include duration epistaxis , Hoag Epistaxis Severity Score ( ESS ) , quality life survey , satisfaction treatment , hemoglobin ferritin level , transfusion requirement , treatment failure . The spray : saline spray ( Placebo ) ; estriol 0.1 % methylcellulose suspension ( EST ) ; tranexamic acid 10 % saline ( TA ) , bevacizumab 1 % saline ( BEV ) . All spray apply nasal mucosa identical spray bottle dose 0.1 ml per nostril twice daily ( total dose 0.4 ml daily ) . Thus , delivered dos : EST , 0.4 mg/day ; TA , 40 mg/day ; BEV , 4 mg/day .</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Epistaxis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1 . A diagnosis definite possible HHT Curacao criterion ( Shovlin 2000 ) positive DNA test HHT ( characterize disease cause mutation gene cod endoglin , ALK1 , SMAD4 ) . According Curacao criterion , definite diagnosis HHT define least 3 follow criterion possible diagnosis define 2 criterion : 1 . Spontaneous recurrent epistaxis . 2 . Multiple telangiectasias characteristic site ( lip , oral cavity , finger , nose ) . 3 . Visceral lesion gastrointestinal telangiectasias arteriovenous malformation ( AVM ) lung , brain , spine liver . 4 . A history definite HHT first degree relative use criterion . 2 . Epistaxis least 1 minute ( average ) occur least weekly average precede 8 week . 3 . Epistaxis severity score ( ESS ) least 3.0 . 4 . Age least 18 year . 5 . Written inform consent obtain prior study entry . 6 . Subject able willing return outpatient visit . 7 . The epistaxis consider clinically stable past 8 week clinical judgment investigator ( i.e . major change frequency duration epistaxis transfusion requirement ) . 8 . Negative pregnancy test enrollment . 1 . Allergy active treatment agent spray additive . 2 . Estimated life expectancy le 1 year . 3 . A psychiatric substance abuse problem expect interfere study compliance . 4 . History deep venous thrombosis ( DVT ) , pulmonary embolism ( PE ) , acute myocardial infarction ( MI ) , arterial thromboembolism , ischemic stroke past 6 month . 5 . History estrogen receptor positive breast cancer . 6 . History receive 12 unit red blood cell past 12 week . 7 . Presence untreated coagulopathy felt contribute epistaxis . 8 . Presence active disseminate intravascular coagulation . 9 . Uncontrolled hypertension ( SBP &gt; 160 and/or DBP &gt; 100 ) . 10 . Presence untreated brain AVM . 11 . Presence active malignancy brain , lung , colon . 12 . Presence symptomatic heart failure . 13 . Use estrogens , epsilon aminocaproic acid , tranexamic acid , thalidomide route 1 week past 12 week . Any use VEGF inhibitor route past 24 week . 14 . Baseline use follow anticoagulant allow : warfarin vitamin K antagonists dose ; unfractionated low molecular weight heparin standard dos treatment venous thromboembolism ( VTE ) ; aspirin &gt; 325 mg/day . Baseline use follow anticoagulant allow : heparin standard dos VTE prophylaxis ; clopidogrel ; aspirin â‰¤325 mg/day . 15 . Addition new treatment epistaxis past 12 week ( include laser ablation nasal telangiectasias counter medication ) . 16 . Presence another overt cause ( e.g . overt gastrointestinal bleeding ) felt significantly contribute anemia . 17 . Lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>epistaxis</keyword>
	<keyword>HHT</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>tranexamic acid</keyword>
	<keyword>nosebleed</keyword>
	<keyword>estrogen</keyword>
</DOC>